![](/img/cover-not-exists.png)
397 Fifty two-week efficacy and safety results from SPIRIT-P1: A Phase 3 study of ixekizumab in patients with active psoriatic arthritis
Mease, P., Okada, M., Kishimoto, M., Shuler, C., Carlier, H., Lin, C., Mou, J., Moriarty, S.R., Lee, C., Gladman, D., Satler, M.Volume:
137
Language:
english
Journal:
Journal of Investigative Dermatology
DOI:
10.1016/j.jid.2017.07.592
Date:
October, 2017
File:
PDF, 431 KB
english, 2017